Cibus (NASDAQ:CBUS) Price Target Lowered to $17.50 at Canaccord Genuity Group

Cibus (NASDAQ:CBUS - Free Report) had its price objective decreased by Canaccord Genuity Group from $18.00 to $17.50 in a research note released on Monday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

Separately, HC Wainwright restated a "buy" rating and issued a $25.00 price target on shares of Cibus in a research note on Friday, March 21st.

Cibus Price Performance

Cibus stock traded up $0.46 during mid-day trading on Monday, reaching $2.62. 179,196 shares of the company traded hands, compared to its average volume of 176,341. Cibus has a 52-week low of $1.40 and a 52-week high of $18.75. The firm has a market capitalization of $86.07 million, a price-to-earnings ratio of -0.12 and a beta of 1.70. The firm's 50 day moving average price is $1.99 and its 200 day moving average price is $2.80.

Cibus (NASDAQ:CBUS - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.04). The business had revenue of $1.03 million for the quarter, compared to analysts' expectations of $1.15 million. Cibus had a negative net margin of 10,724.78% and a negative return on equity of 28.17%. On average, sell-side analysts anticipate that Cibus will post -2.96 EPS for the current year.

Institutional Trading of Cibus

Large investors have recently modified their holdings of the company. Barclays PLC lifted its holdings in Cibus by 35.1% during the fourth quarter. Barclays PLC now owns 27,375 shares of the company's stock worth $76,000 after buying an additional 7,106 shares during the period. Northern Trust Corp raised its position in shares of Cibus by 9.2% in the 4th quarter. Northern Trust Corp now owns 152,122 shares of the company's stock worth $423,000 after acquiring an additional 12,832 shares in the last quarter. IFP Advisors Inc purchased a new stake in shares of Cibus during the 4th quarter worth $36,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Cibus by 32.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 55,142 shares of the company's stock worth $103,000 after purchasing an additional 13,583 shares during the last quarter. Finally, Blair William & Co. IL bought a new stake in Cibus during the first quarter valued at about $28,000. Hedge funds and other institutional investors own 33.81% of the company's stock.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.